Zobrazeno 1 - 10
of 195
pro vyhledávání: ''
Autor:
Donald P. Bottaro, Ralph E. Parchment, Larry Rubinstein, Barry C. Johnson, Woondong Jeong, Young H. Lee, Khanh T. Do, Apurva K. Srivastava, James H. Doroshow, John Wright, Alice P. Chen, S. Kummar, Tony Navas, Andrea Regier Voth, Fabiola Cecchi, Sook Ryun Park
Publikováno v:
Investigational New Drugs
The vascular endothelial growth factor (VEGF)/VEGFR and hepatocyte growth factor (HGF)/c-MET signaling pathways act synergistically to promote angiogenesis. Studies indicate VEGF inhibition leads to increased levels of phosphorylated c-MET, bypassing
Publikováno v:
Investigational New Drugs
Summary Background There is a need to establish an effective neoadjuvant therapy for soft tissue sarcomas (STSs). We previously showed that apatinib, administered in combination with doxorubicin-based chemotherapy, improves the efficacy of treatment.
Autor:
Kazunaga Ishigaki, Tsuyoshi Hamada, Kazuhiko Koike, Suguru Mizuno, Hirofumi Kogure, Naminatsu Takahara, Hiroharu Yamashita, Ryunosuke Hakuta, Tomotaka Saito, Hironori Ishigami, Hiroyuki Isayama, Kei Saito, Tatsuya Sato, Yousuke Nakai, Yasuyuki Seto
Publikováno v:
Investigational New Drugs. 39:175-181
Purpose. A phase I study of intraperitoneal paclitaxel (ip PTX) combined with gemcitabine (GEM) plus nab-paclitaxel (nab-PTX) (GnP) was conducted to determine the maximum tolerated dose (MTD) and the recommended dose (RD) in pancreatic cancer patient
Autor:
Masahiro Kitada, Hidetoshi Kawaguchi, Masaya Hattori, Satoshi Morita, Shinji Ohno, Yoshie Hasegawa, Toshinari Yamashita, Masahiro Kashiwaba, Kazuhiro Yanagihara, Teru Kawasoe, Norikazu Masuda, Tetsuhiro Yoshinami, Kazutaka Narui, Hiroko Bando, Nobuki Matsunami, Rikiya Nakamura, Hiroshi Yano, Masakazu Toi, Takeshi Nagashima
Publikováno v:
Investigational New Drugs
SummaryPurpose To date, it is not clear which anticancer agent is useful in combination with trastuzumab and pertuzumab As the first and second selective regimens for advanced or metastatic breast cancer (AMBC), this multicenter, open-label, phase II
Autor:
Pete Weber, Fuxin Shi, John Soglia, John Keilty, Heather Wolff, Ryan McCarthy, Jason Kropp, Vissia Viglietta, Yong Ren, Hu Qi-Ying
Publikováno v:
Investigational New Drugs
SummaryCisplatin is a widely used chemotherapy for the treatment of certain solid tumors. Ototoxicity and subsequent permanent hearing loss remain a serious dose-limiting side effect associated with cisplatin treatment. To date, no therapies have bee
Autor:
An K.L. Reyners, Daan J Touw, K Esther Broekman, Marieke A J Hof, Hans W. Nijman, Jourik A. Gietema, Joop D. Lefrandt, Mathilde Jalving
Publikováno v:
Investigational new drugs, 38(5), 1454-1462. SPRINGER
Investigational New Drugs
Investigational New Drugs
SummaryBackground Metformin use is associated with reduced cancer risk in epidemiological studies and has preclinical anti-cancer activity in ovarian cancer models. The primary objective of this phase I study was to determine the recommended phase II
Autor:
Anthony C. Wood, Sreenivasulu Chintala, Nur P. Damayanti, Nabil Adra, Saby George, Roberto Pili
Publikováno v:
Invest New Drugs
Background Preclinical studies suggested synergistic anti-tumor activity when pairing mTOR inhibitors with histone deacetylase (HDAC) inhibitors. We completed a phase I, dose-finding trial for the mTOR inhibitor everolimus combined with the HDAC inhi
Publikováno v:
Investigational New Drugs. 38:1186-1191
This study was designed to evaluate the efficacy and safety of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment in recurrent or advanced cervical cancer patients. Twenty patients who failed cisplatin/
Autor:
Grace Lin, Carrie Strand, Charles Erlichman, Alex A. Adjei, Jack Fiskum, Michael Menefee, Brian A. Costello, Joleen M. Hubbard, Rui Qin, Paul Haluska, Erin L. Schenk, Joel M. Reid, Jun Yin, Percy Ivy, L. Austin Doyle
Publikováno v:
Invest New Drugs
Purpose. Targeting the vascular endothelial growth factor (VEGF) pathway improves progression free survival in multiple advanced malignancies but durable responses are uncommon. Inhibition of the VEGF pathway at multiple levels of signal transduction
Publikováno v:
Investigational new drugs. 39(6)
PurposeThis study investigated the relationship between the pharmacokinetics and pharmacodynamics of everolimus in patients with metastatic breast cancer (mBC) in real-world practice.MethodsTwenty-two patients with mBC treated with everolimus plus ex